4800 Montgomery Lane
Suite 800
Bethesda, MD 20814
United States
240 497 9024
https://www.nwbio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 25
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Ms. Linda F. Powers J.D. | Chairperson, CEO, President, CFO & Chief Accounting Officer | 1.1M | N/D | 1956 |
Dr. Alton L. Boynton Ph.D. | Founder, Chief Scientific Officer, Secretary & Director | 450k | N/D | 1945 |
Dr. Marnix L. Bosch M.B.A., Ph.D. | Chief Technical Officer | 597.5k | N/D | 1959 |
Mr. Leslie J. Goldman | Senior VP & General Counsel | 825k | N/D | 1945 |
Ms. Jean M. Davis | Chief Information Officer | 258.78k | N/D | 1972 |
Mr. David Innes | Vice President of Investor Relations | N/D | N/D | N/D |
Mr. Pankaj R. Shah C.A., CPA | Financial Controller | N/D | N/D | N/D |
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
La calificación ISS Governance QuickScore de Northwest Biotherapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.